Built for teams
expanding R&D scope
Intangia is built for growth-minded biotech and pharma teams deploying capital into new targets, new indications, and new therapeutic strategies. We help R&D, portfolio, and BD leaders make smart, mission-critical decisions before consensus forms.
Built for teams
expanding R&D scope
Intangia is built for growth-minded biotech and pharma teams deploying capital into new targets, new indications, and new therapeutic strategies. We help R&D, portfolio, and BD leaders make smart, mission-critical decisions before consensus forms.
Built for teams
expanding R&D scope
Intangia is built for growth-minded biotech and pharma teams deploying capital into new targets, new indications, and new therapeutic strategies. We help R&D, portfolio, and BD leaders make smart, mission-critical decisions before consensus forms.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Built for
Built for
Built for
Supporting those who decide
where R&D capital goes.
Supporting those who decide
where R&D capital goes.
Supporting those who decide
where R&D capital goes.
Biotech Companies
For ambitious biotechs expanding scientific and clinical scope. Capital is available; the constraint is deciding which expansion bets merit backing.
Identify and rank new therapeutic targets based on durable translational momentum rather than transient market hype.
Generate evidence-linked rationale that leadership teams and boards can stand behind during mission-critical pivots.
Visualize how emerging scientific mechanisms are taking hold in specific indications before they become industry consensus.
Identify and rank new therapeutic targets based on durable translational momentum rather than transient market hype.
Generate evidence-linked rationale that leadership teams and boards can stand behind during mission-critical pivots.
Visualize how emerging scientific mechanisms are taking hold in specific indications before they become industry consensus.
Identify and rank new therapeutic targets based on durable translational momentum rather than transient market hype.
Generate evidence-linked rationale that leadership teams and boards can stand behind during mission-critical pivots.
Visualize how emerging scientific mechanisms are taking hold in specific indications before they become industry consensus.
Biopharma & Pharma
For larger organisations allocating capital across many competing portfolios, disease areas, and platforms. Governance requires repeatable, auditable decision processes.
Apply a consistent framework to evaluate emerging science across modalities, indications, and portfolios.
Integrate internal data with external evidence to surface themes before they become industry consensus.
Produce decision-ready artefacts designed for interrogation and defence in governance and portfolio reviews.
Business Development Teams
For teams licensing, partnering, or positioning assets in crowded and competitive landscapes. The challenge is separating durable momentum from transient hype.
Surface emerging mechanism–indication fits before they are obvious to the broader market.
Build defensible deal rationale backed by deep, evidence-linked translational signals.
Map crowded landscapes to identify under-recognised opportunities with forming momentum.
Life Sciences Investors
For venture, growth, crossover, and public market investors seeking an edge ahead of pricing and consensus.
Identify emerging mechanisms and indications with early, data-backed translational momentum.
Distinguish durable scientific trends from narrative-driven or short-lived hype cycles.
Support investment theses and diligence with repeatable, compounding evidence trails across portfolios.
FAQ
FAQ
FAQ
Got questions?
Start here.
WHAT CAN INTANGIA DETECT?
Intangia detects emerging scientific trends before they become visible to competitors. We identify which biological targets, mechanisms, modalities, and therapeutic combinations are gaining momentum in research, before they hit mainstream attention. This includes patterns across papers, patents, and clinical trials that signal genuine innovation waves rather than noise.
Who is it for?
Intangia is built for pharmaceutical decision makers who need predictive foresight, not reactive search: R&D Strategy Leaders identifying next generation targets and mechanisms BD Teams prioritising partnership opportunities with systematic screening Investment Teams sourcing early stage deals and validating thesis timing IP Strategy Leaders finding white space areas for defensive positioning Corporate Strategy Teams allocating capital to high momentum areas If your job involves answering "what should I be looking at?" rather than "what do I already know about?", Intangia is for you.
How does it work?
Intangia processes millions of papers, patents, and clinical trials to extract meaningful scientific entities: targets, mechanisms, diseases, modalities. We then apply proprietary burst detection algorithms with multi-algorithm consensus and statistical validation to identify when specific concepts suddenly accelerate together. This creates innovation waves. Clusters of related concepts showing coordinated momentum. We track how these waves translate from research into patents and clinical trials, giving you validated predictions about what's emerging. You get momentum scores, translation probabilities, and company level intelligence. Not search results.
Is my data private?
Yes. Intangia processes public scientific data (papers, patents, clinical trials), but your usage, queries, searches, and strategic focus areas remain completely private. We don't share customer activity with anyone. Your competitive intelligence stays yours. If you connect internal data sources (optional), those remain siloed within your organisation's instance.
How do I get started?
We typically begin with a focused pilot on a specific therapeutic area or target class relevant to your pipeline. This lets you validate Intangia's predictive accuracy against known outcomes and recent developments in your field. From there, we expand coverage based on your strategic priorities. Get in touch or book a demo.
WHAT CAN INTANGIA DETECT?
Intangia detects emerging scientific trends before they become visible to competitors. We identify which biological targets, mechanisms, modalities, and therapeutic combinations are gaining momentum in research, before they hit mainstream attention. This includes patterns across papers, patents, and clinical trials that signal genuine innovation waves rather than noise.
Who is it for?
Intangia is built for pharmaceutical decision makers who need predictive foresight, not reactive search: R&D Strategy Leaders identifying next generation targets and mechanisms BD Teams prioritising partnership opportunities with systematic screening Investment Teams sourcing early stage deals and validating thesis timing IP Strategy Leaders finding white space areas for defensive positioning Corporate Strategy Teams allocating capital to high momentum areas If your job involves answering "what should I be looking at?" rather than "what do I already know about?", Intangia is for you.
How does it work?
Intangia processes millions of papers, patents, and clinical trials to extract meaningful scientific entities: targets, mechanisms, diseases, modalities. We then apply proprietary burst detection algorithms with multi-algorithm consensus and statistical validation to identify when specific concepts suddenly accelerate together. This creates innovation waves. Clusters of related concepts showing coordinated momentum. We track how these waves translate from research into patents and clinical trials, giving you validated predictions about what's emerging. You get momentum scores, translation probabilities, and company level intelligence. Not search results.
Is my data private?
Yes. Intangia processes public scientific data (papers, patents, clinical trials), but your usage, queries, searches, and strategic focus areas remain completely private. We don't share customer activity with anyone. Your competitive intelligence stays yours. If you connect internal data sources (optional), those remain siloed within your organisation's instance.
How do I get started?
We typically begin with a focused pilot on a specific therapeutic area or target class relevant to your pipeline. This lets you validate Intangia's predictive accuracy against known outcomes and recent developments in your field. From there, we expand coverage based on your strategic priorities. Get in touch or book a demo.
WHAT CAN INTANGIA DETECT?
Intangia detects emerging scientific trends before they become visible to competitors. We identify which biological targets, mechanisms, modalities, and therapeutic combinations are gaining momentum in research, before they hit mainstream attention. This includes patterns across papers, patents, and clinical trials that signal genuine innovation waves rather than noise.
Who is it for?
Intangia is built for pharmaceutical decision makers who need predictive foresight, not reactive search: R&D Strategy Leaders identifying next generation targets and mechanisms BD Teams prioritising partnership opportunities with systematic screening Investment Teams sourcing early stage deals and validating thesis timing IP Strategy Leaders finding white space areas for defensive positioning Corporate Strategy Teams allocating capital to high momentum areas If your job involves answering "what should I be looking at?" rather than "what do I already know about?", Intangia is for you.
How does it work?
Intangia processes millions of papers, patents, and clinical trials to extract meaningful scientific entities: targets, mechanisms, diseases, modalities. We then apply proprietary burst detection algorithms with multi-algorithm consensus and statistical validation to identify when specific concepts suddenly accelerate together. This creates innovation waves. Clusters of related concepts showing coordinated momentum. We track how these waves translate from research into patents and clinical trials, giving you validated predictions about what's emerging. You get momentum scores, translation probabilities, and company level intelligence. Not search results.
Is my data private?
Yes. Intangia processes public scientific data (papers, patents, clinical trials), but your usage, queries, searches, and strategic focus areas remain completely private. We don't share customer activity with anyone. Your competitive intelligence stays yours. If you connect internal data sources (optional), those remain siloed within your organisation's instance.
How do I get started?
We typically begin with a focused pilot on a specific therapeutic area or target class relevant to your pipeline. This lets you validate Intangia's predictive accuracy against known outcomes and recent developments in your field. From there, we expand coverage based on your strategic priorities. Get in touch or book a demo.